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Abstract
Background: The emerging resistance to the extended-spectrum cephalosporins (ESCs) in Neisseria gonorrhoeae
together with increasing incidence of gonorrhoea cases in many countries have been global public health concerns.
However, in recent years the levels of ESC resistance have decreased in several regions worldwide. We describe the
European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) data from 2013, and compare them to
corresponding data from 2009–2012.
Methods: During 2013, N. gonorrhoeae isolates from 21 participating countries were examined. Antimicrobial
susceptibility testing (Etest or agar dilution) was performed for cefixime, ceftriaxone, ciprofloxacin, azithromycin,
spectinomycin and gentamicin. Statistical analyses were performed to identify significant changes in resistance
between years and to investigate associations between patients with resistant gonococcal isolates and collected
epidemiological variables.
Results: In total, 93 (4.7 %) of 1994 isolates displayed resistance to cefixime, representing an increase compared to
the 3.9 % detected in 2012 (p = 0.23). Cefixime resistance was detected in 13 (61.9 %) of the 21 countries. Cefixime
resistance among men who have sex with men was only 1.2 %, compared to 5.6 % and 6.1 % in females and
male heterosexuals, respectively. The univariate analysis confirmed that isolates resistant to cefixime were more likely
to be from females (OR 4.87, p < 0.01) or male heterosexuals (OR 5.32, p < 0.01). Seven (0.4 %) isolates displayed
ceftriaxone resistance (in addition to cefixime resistance) compared to three and 10 isolates in 2012 and 2011,
respectively. All 93 isolates with cefixime resistance were additionally resistant to ciprofloxacin and 16 (17.2 %) were
also resistant to azithromycin. Among all tested isolates (n = 1994), the ciprofloxacin resistance level (52.9 %) was
higher than in 2012 (50.1 %; p = 0.08), and azithromycin resistance (5.4 %) increased since 2012 (4.5 %; p = 0.16).
Conclusions: In 2013, the ESC resistance was again slightly increasing in Europe. This emphasises the importance of
implementing the actions outlined in the European and additional response plans, particularly activities strengthening
the surveillance of antimicrobial resistance. Ceftriaxone combined with azithromycin remains a satisfactory option for
the first-line treatment of gonorrhoea. However novel antimicrobials (new derivatives of previously developed
antimicrobials or newly developed antimicrobials) for effective monotherapy or at least inclusion in new dual
antimicrobial therapy regimens (combined with previously developed antimicrobials or novel antimicrobials) will
likely be required.
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Background
The in vitro resistance emerging in Neisseria gonorrhoeae
internationally to the last remaining options for empiric
first-line treatment of gonorrhoea, the extended-spectrum
cephalosporins (ESCs) cefixime and ceftriaxone, which has
translated into clinical treatment failures, has been well
documented in recent years [1–14]. Some well-
characterised multidrug-resistant N. gonorrhoeae
(MDR-NG) strains have accounted for most of this in
vitro and clinical resistance to the ESCs worldwide,
such as the N. gonorrhoeae multi-antigen sequence
type (NG-MAST) ST1407 or genetically closely related
STs [3–8, 10, 12]. This developing situation along with the
rising incidence of reported gonorrhoea cases in many par-
ticularly high-income countries [15–17], the associated
morbidity of untreated gonorrhoea such as ectopic preg-
nancy and infertility, and the fact that gonorrhoea can sub-
stantially increase HIV transmission [18–20], make
gonorrhoea a global public health problem.
N. gonorrhoeae has a well-documented history of ac-
quiring and developing antimicrobial resistance (AMR)
to all drugs used therapeutically for gonorrhoea [2] and
it could therefore be predicted that N. gonorrhoeae
would develop resistance to the ESCs. In this emergent
situation, there have been significantly increased ef-
forts aiming to retain gonorrhoea as a treatable in-
fection. National and international action plans, such
as the World Health Organization (WHO) global ac-
tion plan [21, 22], the Centers for Disease Control
and Prevention (CDC) response plan [23] and the
European Centre for Disease Prevention and Control
(ECDC) response plan to the threat of MDR-NG
[24] have emphasised the need to scale up AMR sur-
veillance globally, the need for updating national and
international gonorrhoea management guidelines to
include introduction of dual antimicrobial therapy
[25], and information dissemination about the situ-
ation to healthcare professionals, patients and the
public. AMR in N. gonorrhoeae has also been fre-
quently highlighted as a major concern in the
broader AMR reports and strategies [26–28].
In the European Union (EU)/European Economic Area
(EEA), surveillance of AMR in N. gonorrhoeae is per-
formed through the European Gonococcal Antimicrobial
Surveillance Programme (Euro-GASP) [24, 29, 30]. The
programme documented a statistically significant in-
crease in cefixime resistance from 2009 (5.1 %) to 2010
(8.7 %), however after 2010 the cefixime resistance levels
started to decrease to a low of 3.9 % in 2012 [29, 30].
Similar decreases in the resistance to ESCs have also
been documented in other regions [15, 16, 31–36].
The aims of the present study were to describe the
Euro-GASP data from 2013, and compare them to the
Euro-GASP data from 2009–2012.
Methods
Neisseria gonorrhoeae isolates and the Euro-GASP
During 2013, N. gonorrhoeae isolates from 21 participat-
ing countries were examined in the Euro-GASP (Table 1).
Number of countries participating in Euro-GASP in-
creased over time: in 2009, 16 countries participated in
the Euro-GASP; Cyprus, Hungary, Ireland and Norway
joined in 2010; Iceland joined in 2013; Romania partici-
pated only in 2010 and 2011. Isolates were collected dur-
ing two time periods; from April to May, and from
October to November. Nine (43 %) of the countries par-
ticipating in 2013 followed a centralised testing model,
i.e., all antimicrobial susceptibility testing was performed
centrally (in laboratories at Public Health England or
Örebro University Hospital, Sweden) by the Etest for
cefixime and ceftriaxone and agar dilution breakpoint
method for ciprofloxacin, azithromycin and spectino-
mycin, and the full agar dilution method for gentamicin.
The remaining 12 (57 %) countries followed a decentra-
lised testing model, that is, the antimicrobial susceptibil-
ity testing using the Etest or agar dilution method was
performed in their own national reference or local la-
boratory (Table 1). To ensure quality and comparability
of data, all countries performing decentralised testing
fulfilled strict quality criteria, all countries participated
in an annual external quality assessment programme,
and all countries used identical international reference
strains for quality controls. Further details regarding the
Euro-GASP have been published elsewhere [29]. The re-
sistance breakpoints stated by the European Committee
on Antimicrobial Susceptibility Testing (EUCAST) were
used (cefixime/ceftriaxone minimum inhibitory concen-
tration (MIC) > 0.125 mg/L, azithromycin MIC >
0.5 mg/L and ciprofloxacin MIC > 0.06 mg/L) [37]. The
following epidemiological variables were collected and
subsequently categorised as follows: age (< 25 years or
≥ 25 years), sexual orientation and gender (men who
have sex with men (MSM), male heterosexuals and all
women), previous gonorrhoea (yes or no), and concur-
rent chlamydial infection or no chlamydial infection.
Statistical analysis
The statistical significance of any changes in the propor-
tion of isolates with resistance to tested antimicrobials
between years was determined by the Z-test or Fisher’s
exact test if cell numbers were less than 5. A univariate
analysis and multivariable logistic regression analyses of
odds ratios (OR) with 95 % confidence intervals (CI)
were calculated to investigate associations between pa-
tients infected with an isolate displaying resistance to
cefixime, ciprofloxacin or azithromycin, and the col-
lected epidemiological variables. A Pearson χ2-test was
used to test if these odds ratios were significantly different
from one, with a P-value of < 0.05 indicating significance.
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Statistical analysis was performed in STATA v12.1 (Stata-
Corp LP, TX, USA).
Ethics
The present study was a surveillance study, using data from
the Euro-GASP which is implemented through the ECDC
Framework Contract No. ECDC/2013/015. All examined
gonococcal isolates were cultured and preserved as part of
the routine diagnostics (standard care) and no patient iden-
tification information was available in the present study.
Ethical approval was therefore not required.
Results
The results of all the antimicrobial susceptibility testing
are summarised in Table 1. Of the 1994 examined
N. gonorrhoeae isolates collected in 21 EU/EEA coun-
tries in 2013, 4.7 % (93 isolates) displayed resistance to
cefixime (Table 1, Fig. 1). This represented a slight, but
not statistically significant, increase compared to the
3.9 % of resistant isolates detected in 2012 (Z-test,
p = 0.233). Cefixime resistance was detected in 13
(61.9 %) of the 21 countries, and in these countries
cefixime resistance levels ranged from 0.8 % (United
Kingdom) to 15.1 % (Spain) (Table 1). Nineteen (1.0 %)
isolates had a MIC of cefixime of ≥ 0.5 mg/L compared
to three isolates in 2012, and 13 isolates in 2011 (Fish-
er’s Exact test p = 0.001 and p = 0.379, respectively).
These 19 isolates were from Spain (n = 7), Denmark
(n = 3), Germany (n = 3), Austria (n = 2), Greece (n = 1),
Hungary (n = 1), Slovakia (n = 1), and United Kingdom
(n = 1). Seven (0.4 %) isolates displayed ceftriaxone
resistance (six from Spain and one from Germany; all
were additionally resistant to cefixime) compared to
three isolates and 10 isolates in 2012 and 2011, respect-
ively. All 93 isolates with cefixime resistance were
additionally resistant to ciprofloxacin and 16 (17.2 %)
were also resistant to azithromycin. Finally, of the
seven ceftriaxone-resistant isolates, one (0.05 %) was
Table 1 Resistance to cefixime, ciprofloxacin and azithromycin in Neisseria gonorrhoeae isolates from 21 EU/EEA countries, 2013
Country Antimicrobial Method of testing
Cefixime Ciprofloxacin Azithromycin
No. resistant No. tested % No. resistant No. tested % No. resistant No.
tested
%
Austria 7 109 6.4 78 109 71.6 6 109 5.5 Centralised
Belgium 7 110 6.4 62 110 56.4 2 110 1.8 Decentralised – MIC
Cyprus 0 9 0 8 9 88.9 3 9 33.3 Centralised
Denmark 13 110 11.8 64 110 58.2 10 110 9.1 Decentralised – Etest
France 4 112 3.6 50 112 44.6 0 112 0 Decentralised – Etest
Germany 13 101 12.9 64 101 63.4 4 101 4 Centralised
Greece 11 75 14.7 54 75 72 15 66 22.7 Decentralised – Etest
Hungary 6 88 6.8 60 88 68.2 2 88 2.3 Centralised
Iceland 0 5 0 2 5 40 0 5 0 Decentralised – Etest
Ireland 0 103 0 27 103 26.2 3 103 2.9 Decentralised – Etest
Italy 0 100 0 63 100 63 1 100 1 Decentralised – Etest
Latvia 1 38 2.6 10 38 26.3 6 38 15.8 Centralised
Malta 0 31 0 11 31 35.5 0 31 0 Decentralised – Etest
The Netherlands 0 139 0 48 139 34.5 2 139 1.4 Decentralised – Etest
Norway 5 112 4.5 89 112 79.5 12 112 10.7 Centralised
Portugal 0 110 0 52 110 47.3 20 110 18.2 Decentralised – Etest
Slovenia 1 73 1.4 46 73 63 0 73 0 Centralised
Slovakia 5 110 4.5 52 110 47.3 2 110 1.8 Centralised
Spain 18 119 15.1 78 119 65.5 10 119 8.4 Decentralised – MIC
Sweden 0 100 0 60 100 60 9 100 9 Decentralised – Etest
United Kingdom 2 240 0.8 77 240 32.1 1 240 0.4 Decentralised – MIC
Total 93 1994 4.7 1055 1994 52.9 108 1985 5.4
95% CI 3.8 – 5.7 50.7 – 55.1 4.5 – 6.5
EU/EEA, European Union/European Economic Area; MIC, minimum inhibitory concentration using Etest and/or agar dilution method; CI, confidence interval of the
mean %
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also resistant to azithromycin and five (0.3 %) had a
MIC (0.5 mg/L) exactly at the breakpoint for
resistance.
Furthermore, the MIC distribution for ceftriaxone in
2013 compared to the ones in 2011 and 2012 showed a
decreased proportion of highly susceptible gonococcal
isolates (MIC ≤ 0.002 mg/L) as well as increased propor-
tions of isolates with higher MICs such as 0.064 mg/L
and 0.125 mg/L (Fig. 2), which is exactly at the resist-
ance breakpoint.
Overall, the ciprofloxacin resistance level of 52.9 %
detected in 2013 was slightly higher than the 50.1 % of
resistance detected in 2012 (Z-test, p = 0.082), continu-
ing the gradually increasing trend observed since 2011
(Fig. 1). For the first time since 2008, azithromycin resist-
ance increased, although the increase was not statistically
significant (4.5 % in 2012, 5.4 % in 2013; Z-test, p = 0.159).
However, only one isolate displayed high-level resistance to
azithromycin (MIC ≥ 256 mg/L; collected in Ireland); high-
level azithromycin-resistant isolates were also detected in
2006 (n = 1), 2007 (n = 4), 2011 (n = 2) and 2012 (n = 3). Fi-
nally, the modal MIC of gentamicin was 8 mg/L
(MIC range: from 1 to 16 mg/L) and no resistance
to spectinomycin (MIC range: from 0.5 to 64 mg/L)
was demonstrated.
In Table 2, the number of patients with isolate suscep-
tibility data (number of resistant isolates) linked with



















































Fig. 2 Ceftriaxone MIC distributions for Neisseria gonorrhoeae isolates in EU/EEA during 2009–2013
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analysis, the only significant associations with cefixime
resistance were being male heterosexual (OR male
heterosexual vs. MSM 5.32, CI 2.12–13.3, p = 0.0001) or
female (OR female vs. MSM 4.87, CI 1.89–12.6,
p = 0.0003). For azithromycin, the univariate analysis
revealed associations between azithromycin resistance
and male heterosexuals (OR male heterosexual vs. MSM
2.39, CI 1.21–4.69, p = 0.0094). Associations were also
observed between ciprofloxacin resistance and higher
age (OR ≥ 25 years vs. < 25 years 1.36, CI 1.12-1.66,
p = 0.0022), male heterosexuals (OR male heterosexual
vs. MSM 1.7, CI 1.3–2.24, p = 0.0001), females (OR
females vs. MSM 1.34, CI 1.01–1.79, p = 0.0437) and no
concurrent chlamydia infection (OR no concurrent
chlamydia vs. concurrent chlamydia 1.44, CI 1.03-2.02,
p = 0.0313). In the ciprofloxacin multivariable analysis,
the only significant associations remaining were for
ciprofloxacin resistance and being male heterosexual
(aOR: 1.57, CI 1.13–2.18, p = 0.007), and ciprofloxacin
resistance and no concurrent C. trachomatis infection
(aOR: 1.57, CI 1.09-2.24, p = 0.016).
Discussion
The 2013 Euro-GASP data show that the encouraging
recent trends of decreasing cefixime, ceftriaxone, cipro-
floxacin and azithromycin resistance in N. gonorrhoeae
across the EU/EEA region have not been maintained,
although the increases observed in 2013 were not statis-
tically significant. Further data are needed to establish if
the increasing trend will continue. The 2013 data
emphasize the need for continued expansion and
improvement in quality-assured surveillance of gono-
coccal AMR and treatment failures, as described in the
European and other response plans [21–24]. The data
also stress that widespread implementation of current
European management guidelines [25] or similar thera-
peutic regimens [38, 39] recommending ceftriaxone in
combination with azithromycin for first-line treatment
of all cases of uncomplicated gonorrhoea, remains
crucial.
As well as decreases in the level of resistance to ESCs
in the EU/EEA from 2010 to 2012, decreases have also
been observed in other regions with well-developed
surveillance programmes globally [15, 16, 31, 33–36].
Furthermore, despite some rare ESC treatment failures
verified in recent years [3–14], the anticipated number of
reported gonorrhoea treatment failures has not yet materi-
alised, which could also be partly due to a lack of identifi-
cation and under-reporting of treatment failures. The
decrease in ESC resistance in Europe (2010–2012) and in
several additional regions is an extremely interesting and
perplexing situation as decreasing resistance trends have
never been documented for any previously used anti-
microbial in N. gonorrhoeae. The situation is even more
confusing as similar decreasing trends have been wit-
nessed in countries that have not used cefixime as any
main therapeutic agent or have not changed their recom-
mended treatment regimens [31, 33, 35, 36]. The reasons
explaining all these decreases in ESC resistance are most
likely multi-factorial and complex. A number of recent
changes in the diagnostics and management of gonor-
rhoea may have contributed to the decreases in ESC re-
sistance. In many countries, for example, increased use of
more sensitive molecular diagnostics and increased testing
of extra-genital sites, including the pharynx, among MSM
might have contributed to reducing the reservoir of strains
such as the NG-MAST ST1407 as effective diagnostics al-
lows the administration of appropriate antimicrobial ther-
apy; implementation of updated management guidelines
recommending dual antimicrobial therapy could similarly
have more effectively targeted resistant strains; education
to healthcare professionals is also likely to have contrib-
uted to a more effective implementation of testing and
treatment guidelines. The decrease in ESC resistance
may also be due to an epidemiologic replacement of the
MDR-NG ST1407 clone by other STs, which might poten-
tially have been affected also by some type of partial
immunity to the widely spread ST1407 from prior infec-
tion (17 % - 21 % of patients reported having had a previ-
ous gonorrhoea infection during years 2009 – 2013 [29]).
Clearly, sufficient understanding regarding the gonococcal
population dynamics, including epidemiologic curves for
single strains, is lacking. In the Euro-GASP, a molecular
typing study examining the 2013 isolates and associated
AMR and epidemiologic data is currently underway. This
study should further elucidate the perplexing situation
with the initially decreasing ESC resistance trends that
started to once again increase in 2013.
Table 2 Number of patients with isolate susceptibility data (number of resistant isolates) linked with epidemiological data, i.e., sexual
orientation, age group and concurrent chlamydial infection
Total number of patient variables (no. resistant)
MSM Male heterosexuals Females ≥25 years <25 years Concurrent chlamydia No concurrent chlamydia
Azithromycin 494 (14) 369 (24) 302 (16) 1391 (72) 553 (35) 183 (3) 658 (20)
Ciprofloxacin 496 (210) 376 (209) 302 (150) 1399 (769) 554 (262) 183 (69) 658 (307)
Cefixime 496 (6) 376 (23) 302 (17) 1399 (68) 554 (22) 183 (3) 658 (13)
MSM, men who have sex with men
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It is also crucial to emphasize that the resistance level to
both cefixime and ciprofloxacin is higher in the heterosex-
ual community. In 2013, cefixime resistance was signifi-
cantly associated with heterosexual orientations: among
MSM only 1.2 % of isolates were resistant to cefixime, com-
pared to 5.6 % and 6.1 % in females and male heterosexuals,
respectively. In the Euro-GASP, this trend was also earlier
identified analysing material from 2009 to 2011 [40]. Due
to the severe complications and sequelae resulting from as-
cending infection, the risk of untreated or inappropriately
treated gonorrhoea is of particular concern in women
where the infection is also much harder to diagnose and is
often asymptomatic in nature. Hopefully, the ongoing mo-
lecular typing study examining the 2013 European gono-
coccal isolates and associated AMR and epidemiologic data
will be able to further elucidate also the associations be-
tween AMR and sexual orientation, as well as additional
epidemiological variables.
The main inherent limitations in the Euro-GASP have
been detailed previously in the European response plan
[24], and mostly include issues regarding the number
and representativeness of gonococcal isolates and associ-
ated patients. Efforts are underway to address these
limitations: in 2014, several additional countries have
joined the Euro-GASP, an increased number of isolates
with associated epidemiologic metadata are available
from many countries, and a comprehensive review of
the longitudinal AMR and epidemiological surveillance
data to identify areas where representativeness needs to
be improved is in progress. Nevertheless, in 2013, 21
(68 %) of the 31 EU/EEA countries were already partici-
pating in the Euro-GASP, which should provide a
relatively effective evidence base for the gonococcal
AMR situation in the EU/EEA region.
Conclusions
Even though slight decreases in the ESC resistance were
documented in recent years in Europe and several other
regions globally, in 2013 the ESC resistance was once
again increasing in Europe. Overall, this might be a time of
‘calm before the storm’ and efforts to keep gonorrhoea as a
treatable infection need to be sustained. N. gonorrhoeae has
already shown its capacity to develop high-level resistance
to ceftriaxone [2, 6, 9] and, based on the well-documented
history regarding all antimicrobials previously used for gon-
orrhoea treatment, it is likely that it is only a matter of time
before ceftriaxone-resistant strains with sufficient biological
fitness emerge and start to spread internationally. National
and international surveillance of N. gonorrhoeae AMR
(including collection of appropriate associated epide-
miologic metadata), treatment failures and ideally also
antimicrobial use/misuse, as well as implementation of
recommended dual antimicrobial treatment regimens
(ceftriaxone plus azithromycin) needs to be maintained
and in several areas further strengthened to provide
more reliable evidence for policy makers and to inform
antibiotic prescription protocols. The work outlined in
the European [24] and additional response plans [21–23]
needs to be further implemented, and a close collaboration
between the Euro-GASP and additional GASPs internation-
ally [41] in liaison with the WHO Global GASP is crucial.
The number of cases of gonorrhoea reported to the ECDC
has been increasing annually since 2008; 52,995 cases were
reported in 2013, which is an 11 % increase from the previ-
ous year (47,641 cases in 2012) [42]. This increasing gonor-
rhoea incidence, along with the slight rise of ESC resistance
described in this study, confirms the importance of anti-
microbial susceptibility surveillance for this disease. Pres-
ently, ceftriaxone combined with azithromycin remains a
satisfactory option for the first-line treatment of gonor-
rhoea. However, novel antimicrobials (new derivatives of
previously developed antimicrobials or newly developed an-
timicrobials) for effective monotherapy or at least inclusion
in new dual antimicrobial therapy regimens (combined with
previously developed antimicrobials or other novel antimi-
crobials) will ultimately be required if the upturn seen in
2013 is sustained into future years.
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